Navigation Links
Sanofi Withdraws Anti-obesity Drug in US

French pharmaceutical group Sanofi-Aventis said Friday it had withdrawn an application for regulatory approval for its anti-obesity drug Acomplia in the United States.

A panel of experts from the US Food and Drug Administration concluded earlier this month that the dieting treatment, referred to as rimonabant by the company, was unsafe and should not be sold in the United States.

"Sanofi-Aventis will work towards submitting the rimonabant file to the FDA at a future date," the company said, adding that it will "undertake the necessary discussions with the FDA to determine the required modifications to its file."

The FDA's expert panel concluded that suicidal thoughts appeared to be a side-effect of taking Acomplia, which has been authorised in the European Union.

The FDA was expected to heed the opinion of the panel of experts and block the sale of the drug.

Sanofi had previously forecast annual sales of 3.0 billion euros (4.0 billion dollars) for the drug.

In a separate development, European regulators said they were reviewing data on the psychiatric effects of Acomplia.

The European Medicines Agency (EMEA) said it expected to announce its conclusions at the end of a July 16-19 meeting.

The agency "is currently reviewing the available data on psychiatric events (in particular suicidal ideation and depression-related events)," it said.

Acomplia has been authorised in 37 countries and is currently sold in 18.


'"/>




Page: 1

Related medicine news :

1. FDA Gives Green Signal To Sanofi-Aventis SAs Cancer Drug Taxotere
2. Sanofi-Aventis sets the ball rolling for trials of H7N1 bird flu vaccine
3. Diabetes II May Be Controlled By Sanofis New Obesity Pill
4. Sanofi-Aventis Allows Thais To Make Plavix
5. Bayer Voluntarily Withdraws BAYCOL - A Drug Associated With 50 Deaths
6. Hospital Withdraws McDonalds Reward Scheme
7. Beef Firm in US Withdraws Its Products from Markets After E. Coli Outbreak.
8. Anti-obesity drugs for FDA approval
9. Canada Confronts Obesity Head-on, Anti-obesity Campaign on Fast Track
10. Anti-obesity Drugs Claimed Additional Benefits on cardiometabolic Risk Factors Questioned
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/4/2016)... ... May 04, 2016 , ... The manufacturer of the ... kicking trainers to St. Jude Children’s Research Hospital to benefit families dealing with ... band designed to teach children how to kick a soccer ball correctly. The ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... provider serving families of Camas and Vancouver, WA, has announced the latest ... the National Breast Cancer Foundation and their Mammography Program, which provides free ...
(Date:5/4/2016)... ... May 04, 2016 , ... IsoComforter, Inc., one ... of the innovative newly improved Iso-Hip Wrap. The newly designed hip wrap ... enhances comfort and enables the patient to enjoy the benefits of cold therapy ...
(Date:5/4/2016)... , ... May 04, 2016 , ... A new collaboration ... world. The Duke Clinical Research Institute (DCRI) and analytics leader SAS will provide researchers ... data collected by the Duke University Health System. , The DCRI and SAS ...
(Date:5/4/2016)... ... May 04, 2016 , ... Slepkow Slepkow & ... one of the top website design companies to create a state of the ... to the law firm's main practice areas. These practice areas include: real estate, ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... -- According to market research "Global Magnetic ... Demand Forecast to 2022 - Industry Insights by Architecture ... High Field, Low to Mid Field, and Ultra High ... Vascular, Breast, Pelvic and Abdomen, Cardiac, and Other)" P&S ... was valued at $5,351.7 million in 2015, and it ...
(Date:5/3/2016)... May 3, 2016 ... dass sie einen entscheidenden Meilenstein durch diese ... Aufruf zum Handeln, um Patientenresultate  bei Verdauungs- ... zu Fortschritten im Verständnis der Hepatischen Enzephalopathie ... Bewusstsein für Hepatische Enzephalopathie in der Öffentlichkeit ...
(Date:5/2/2016)...  Celsion Corporation (NASDAQ: CLSN ), an ... the first cohort of patients in its Phase ... combining GEN-1, the Company,s DNA-based immunotherapy, with the ... patients with advanced ovarian cancer who will undergo ... the first three patients dosed, GEN-1 plus standard ...
Breaking Medicine Technology: